

How Pfizer Scaled Up Manufacturing of Their Breakthrough Vaccine to Help Prevent the Spread of COVID-19

At Pfizer, we worked at an unprecedented speed to execute one of the most successful manufacturing operations and distributions in history to help prevent COVID-19.




Manufacturing Capabilities

Pfizer operates one of the most sophisticated supply chain systems in the industry, with 37 owned sites across 25 countries and more than 300 suppliers globally.



For biologics, vaccines & sterile injectables, we reach **1.4 billion patients**
Reaching 1 out of every 6 people




An Unprecedented Manufacturing Success

In 2022, Pfizer met its commitment to manufacture more than 4.5 billion doses of the Pfizer-BioNTech COVID-19 Vaccine worldwide.

Pfizer has manufacturing and distribution sites across the world for the COVID-19 vaccine.

Global PGS Map



How It Happened

Pfizer's manufacturing and supply chain professionals took several steps to accelerate the scale-up and manufacturing of the vaccine to ensure it was one of the most successful manufacturing operations in history.

- **Upgrading technology** to enable rapid facility, equipment and process design planning
- **Maintaining two parallel supply chains** for appropriate redundancies
- **Modifying facilities** for the vaccine formulations and re-prioritizing capacity
- **Hiring and training staff** to give our operations even more support and flexibility
- **Investing at risk** so we can quickly produce as many doses of vaccine as possible
- **Made process improvements** to increase production